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Abstract
Carnosine is a naturally occurring pleotropic dipeptide which influences multiple deleterious mechanisms that are
activated during stroke. Numerous published studies have reported that carnosine has robust efficacy in ischemic
stroke models. To further evaluate these data, we have conducted a systematic review and meta-analysis of published
studies. We included publications describing in vivo models of ischemic stroke where the neuroprotective efficacy of
carnosine was being evaluated through the reporting of infarct volume and/or neurological score as outcomes. Overall
efficacy was evaluated using weighted mean difference random effects meta-analysis. We also evaluated for study quality
and publication bias. We identified eight publications that met our inclusion criteria describing a total of 29 comparisons
and 454 animals. Overall methodological quality of studies was moderate (median¼ 4/9). Carnosine reduced infarct
volume by 29.4% (95% confidence interval (CI), 24.0% to 34.9%; 29 comparisons). A clear dose-response effect was
observed, and efficacy was reduced when carnosine was administered more than 6 h after ischemia. Our findings suggest
that carnosine administered before or after the onset of ischemia exhibits robust efficacy in experimental ischemic
stroke. However, the methodological quality of some of the studies was low and testing occurred only in healthy young
male animals.
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Introduction
Over 15 million people suﬀer a stroke every year
worldwide causing nearly six million deaths and leaving
another ﬁve million people permanently disabled.
The only approved drug for acute stroke is tissue plas-
minogen activator (tPA) but this drug has a short
therapeutic time window of 4.5 h which limits the
number of patients that are eligible to receive it.1,2 An
urgent need exists for safe and eﬀective therapies.2
Despite promising preclinical studies, no drugs have
shown eﬃcacy in clinical trials.2,3 One major reason for
this is that most previous strategies have focused on
modifying a single pathway or category of injury,
whereas ischemia leads to a complex cascade of numer-
ous biochemical and molecular events, ultimately caus-
ing the loss of cellular integrity and tissue destruction.2
It is highly desirable, therefore, to develop therapies
which inﬂuence multiple pathways. Another reason
that preclinical data have not translated to eﬃcacy in
clinical trials is that there has been poor experimental
design or incomplete testing in the preclinical studies.2,4
Carnosine (beta-alanyl-L-histidine) is a naturally
occurring dipeptide that is abundant in many animal
tissues including brain.5 It has numerous properties
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that may be beneﬁcial in limiting ischemia-induced
brain injury. These include antioxidant, anti-
excitotoxic, metal ion chelating, anti-matrix metallo-
proteinase, and intracellular pH buﬀering.3,6–11 All of
these processes play an important role in the pathogen-
esis of brain infarction. Carnosine has been reported to
be highly protective in both permanent and transient
cerebral ischemia models by inﬂuencing multiple mech-
anisms including the attenuation of oxidative stress,
apoptosis, and autophagy.7,9,12 An additional import-
ant property of carnosine is that it can cross the blood–
brain barrier.2
However, to date, there has been no quantitative
appraisal of the published data. Herein, we present a
systematic review and meta-analysis of published stu-
dies using focal ischemia models of experimental
stroke.
Materials and methods
Search strategy
We searched PubMed (1966–May 2016), Embase (1947–
May 2016) and Web of Science (1900–May 2016) elec-
tronic databases using the search terms: (stroke OR
(cerebral OR brain OR focal) AND (ischemia OR ische-
mic OR ischemia OR ischemic)) OR cerebrovascular OR
middle cerebral artery OR MCA OR middle cerebral
artery occlusion OR MCAO OR anterior cerebral
artery OR ACA OR anterior cerebral artery
occlusion OR ACAO OR experimental stroke AND
(B-Alanyl-L-Histidine) OR (B-AlanylHistidine) OR
(Beta-alanyl-L-histidine) OR (Beˆta-Alanyl-L-
Histidine) OR (Carnosina) OR (L-Carnosine) OR
(N-Acetyl-Carnosine) OR (N-Ace´tyl-Carnosine) OR
(N-Acetyl-L-Carnosine) OR (N-Ace´tyl-L-Carnosine)
OR (beta-Alanyl-L-histidine) OR (Ignotine) OR (2-(3-
aminopropanoylamino)-3-(3H-imidazol-4-yl)propanoic
acid) OR (beta-ALA-HIS) OR (L-Histidine,.beta.-
alanyl-) OR (L-alpha-ALANYL-L-HISTIDINE) OR
(L-Histidine, N-.beta.-alanyl-) OR (2-(3-aminopropa-
noylamino)-3-(1H-imidazol-5-yl)propanoic acid) OR
(2-(3-amino-propanoylamino)-3-(1H-imidazol-4-yl)-pro-
pionic acid)) NOT (liver OR kidney OR coronary OR
myocardial OR testis OR testicular OR gastric OR mes-
enteric OR skeletal) limited to animals. Searches were
limited to publications in English.
Inclusion criteria
Two investigators (CKD and RGK) reviewed publica-
tions based on their titles and abstracts. Only studies
evaluating the eﬀect of carnosine in animal models
using focal cerebral ischemia-induced by occlusion of
the middle or anterior cerebral artery or their branches,
compared with animal models receiving no carnosine
were included in our review. Any route and dosage of
carnosine administration at any time of delivery
(before, during or after ischemia onset) were included.
We chose infarct volume, as our primary outcome
measure and neurobehavioral score as our secondary
outcome measure.
Quality assessment
Methodological quality of studies was assessed based
on the modiﬁed CAMARADES study quality checklist
comprising the following: (1) publication in a peer-
reviewed journal, (2) statement of control of tempera-
ture, (3) randomization to treatment or control, (4)
blinded induction of ischemia, (5) blinded assessment
of outcome, (6) use of co-morbid animals, (7) sample
size calculation, (8) statement of compliance with
animal welfare regulations, and (9) statement regarding
possible conﬂicts of interest.13 There was no exclusion
based on study quality. The systematic review adopted
preferred reporting items for systematic reviews and
meta-analyses (PRISMA) guidelines.14
Data extraction
From each study, we identiﬁed separate comparisons of
our primary and secondary outcome measures quanti-
ﬁed in a cohort of animal models of ischemic stroke
where some animals had been given carnosine and con-
trol animals not given the treatment. We extracted data
on species, sex, dosage range, time of administration,
anesthetic used, type of ischemia, and route of drug
delivery. The number of animals used, mean, and
standard error of the outcome measure for treatment
and control groups were also extracted. When multiple
groups were served by a single control group, the
weight of these animals in our analysis was adjusted
by dividing by the number of treatment groups the con-
trol cohort served. Where multiple doses of a drug were
given, the ﬁnal aggregate outcome was taken, and the
time of this outcome measure was taken as the time of
assessment. When the data were only represented
graphically or not mentioned at all in a paper, we con-
tacted the authors to obtain raw data. In cases where
there was no response from the authors, we either
extracted the data from graphs published in their
paper using the software Universal Desktop Ruler or
where this was not possible we went on to exclude those
studies. All data were extracted by two, non-blinded,
reviewers (CKD and RGK).
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Data analysis
For infarct size, we calculated a normalized mean dif-
ference eﬀect size for each comparison (normalized as a
percentage of the mean in the control group) and com-
bined these in a weighted mean diﬀerence meta-analysis
using a random eﬀects model.15 We used stratiﬁed
meta-analysis to assess for the impact of drug dose;
time of administration; type of ischemia; anesthetic
used; species of animal used; and interval to quantiﬁ-
cation of outcome. The signiﬁcance of diﬀerences
between n groups was assessed by partitioning hetero-
geneity and by using the 2 distribution with n1
degrees of freedom (df). To allow for multiple
comparisons, we set our signiﬁcance level using
Bonferroni correction to p< 0.01 and p< 0.007 for
study quality and study characteristics variables,
respectively. We assessed for publication bias using
funnel plot.
Results
Our search of the literature identiﬁed 202 publications.
After screening, only eight full articles were found to
describe the eﬀect of carnosine in animal models of
focal cerebral ischemia and met our inclusion
criteria.7–11,16–18Details of the review process are dis-
played in the PRISMA ﬂow diagram (Figure 1).
Figure 1. Flow diagram for studies included in this meta-analysis.
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A summary of study characteristics of included publi-
cations are shown in Table 1. In total, studies included
in our analysis reported data from 454 animals contri-
buting to 29 comparisons and were done by 4 diﬀerent
research groups. All eight studies reported infarct size
and four studies also reported a neurobehavioral score
(127 animals in 7 comparisons). Only one study
reported mortality data and therefore the inﬂuence of
carnosine on mortality as an outcome measure was not
analyzed. Only one study reported data from transient
middle cerebral artery ischemia (Table 1).8 The data for
transgenic mice from Shen’s paper were excluded as it
was beyond the scope of our study.16
Reported study quality
All eight studies included in our analysis were published
in peer-reviewed journals. Only one study reported
having performed a sample size calculation. None of
the studies included a statement of a potential conﬂict
of interest. Total reported study quality score for each
paper included in our review is summarized in Table 2.
Median reported study quality score was 4 (interquar-
tile range, 3–6) for the eight papers.
Sample sizes were generally small; the median
number of animals per group was 10 in the control
group (interquartile range, 7–14) and 13 in the treat-
ment group (interquartile range, 7–15). Five studies
reported that they randomly allocated animals to treat-
ment group and control groups (63%); two studies
reported blinding their assessment of outcome (25%);
three studies reported masked induction of ischemia
(38%); and all studies reported regulating the tempera-
ture of the animals during the induction of ischemia.
Seven studies reported compliance with animal wel-
fare regulations.
Efficacy
Results on infarct size for each comparison within the
eight studies are summarized in supplementary Table 1.
Carnosine treatment reduced infarct volume by 29.4%
(95% CI, 24.0% to 34.9%; 29 comparisons;
Figure 2(a)). Observed heterogeneity was low
(2¼ 28.7, df¼ 28, p¼ 0.426). We did not observe any
evidence of publication bias in the funnel plot
(Figure 2(b)); Egger test p¼ 0.204).
Stratiﬁed meta-analysis was done using the data for
infarct volume. Initially, studies were grouped in terms
of the carnosine dose (Figure 3(a)). Heterogeneity
between dose subgroups was quantiﬁed as Q¼ 12.4,
3df, p¼ 0.006, demonstrating a clear diﬀerence in treat-
ment eﬀect by dose. There was a 38.1% reduction in
infarct size (95% CI, 30.1% to 46.2%) for a dose of
1000mg/kg compared with 23.3% (95% CI, 13.2% to
33.5%) for doses between 500 and 750mg/kg and
13.2% (95% CI, 0.4% to 26.0%) for doses less than
500mg/kg.
In the published data, carnosine dose was con-
founded with a number of other study characteristic
variables. For example, out of the 11 comparisons
involving lower doses (750mg/kg), 10 of them admin-
istered the drug 30min before the induction of ische-
mia. This makes it diﬃcult to identify whether a
diﬀerence in treatment eﬀect in this portion of the
data was associated with the dose or the time of
administration.
In order to conﬁrm the eﬀect of dose independently
from administration time, we looked at the dose eﬀect
for comparisons involving drug administration 30min
prior to the induction of ischemia only. The estimated
eﬀect of the 1000mg/kg dose in this subset was similar
to that in the full analysis. This suggests that the smaller
eﬀect estimates in the lower dose levels are indeed asso-
ciated with the lower dose rather than the early admin-
istration time.
To avoid bias due to confounding factors such as
dose, subsequent stratiﬁed meta-analysis was per-
formed in an exploratory manner using only the 18
comparisons involving higher doses of carnosine
(1000mg/kg or more).
Looking at the eﬀect of administration time, the
between-subgroup heterogeneity was Q¼ 6.29; 2df;
p¼ 0.0431. Allowing for multiple testing, this was not
statistically signiﬁcant. However, it is worth noting that
the estimated reduction in infarct size was similar (42–
43%) when carnosine was administered either 30min
prior to ischemia (95% CI, 28.0% to 55.9%) or
within 6 h after ischemia (95% CI, 32.7% to 53.0%),
whereas treatment more than 6 h after induction of
ischemia was associated with only a 19% reduction
(95% CI, 3.0% to 35.5%) in infarct size (Figure 3(b)).
Regarding the other potential eﬀect modiﬁers, no
signiﬁcant between-subgroup heterogeneity was identi-
ﬁed for study characteristics (Figure 3(b)). Nor was
there any evidence of any relationship between eﬀect
size and any of the study quality parameters, including
blinding of assessments (p¼ 0.53) and randomization
(p¼ 0.62).
Bubble plots (Figure 4) were used to further illus-
trate the eﬀects of dose (log scale) and administration
time.
Stratiﬁed meta-analysis for neurobehavioral score
was not performed due to insuﬃcient number of
comparisons.
Discussion
To the best of our knowledge, this is the only systematic
review and meta-analysis which has evaluated the
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eﬃcacy of carnosine in animal models. Our analysis of
data from eight stroke studies (454 animals), shows that
carnosine has neuroprotective eﬃcacy in reducing
infarct size in animal models of stroke. We found that
the dose of carnosine that was associated with the
greatest eﬃcacy was 1000mg/kg. The observed treat-
ment eﬀects were larger in studies, where drug was
administered immediately or up to six hours ( 6 h)
after the induction of ischemia. However, some eﬃcacy
was even observed when carnosine was administered
over 6 h after the induction of ischemia, albeit with a
smaller treatment eﬀect. This time window is clinically
relevant and has translational implications as the
median time for stroke patients to arrive at hospital is
4.3 h.19
Study quality
Study quality overall was moderate. There were three
studies with a quality score above ﬁve. Study quality
criteria such as masked induction of ischemia, random
allocation of animals to group, and blinded assessment
of outcome were not commonly reported. However,
there was no evidence of any relationship between
eﬀect size and any of the study quality parameters,
including blinding of assessments and randomization.
One explanation for this could be that quality param-
eters such as randomization and blinding did occur but
were not reported in those publications.
One of the problems with systematic reviews is that
not all studies that were carried out are published lead-
ing to publication bias. Research with statistically
Table 2. Study quality score.
Author Year 1 2 3 4 5 6 7 8 9
Quality
Score
Bae 20138 X X X X X X 6
Rajanikant 2007 X X 2
Min 2008 X X X X 4
Bae 201311 X X X X X X 6
Shen 2010 X X X 3
Park 2014 X X X 3
Wang 2013 X X X X 4
Baek 2014 X X X X X X 6
Figure 2. (a) Individual comparisons ranked according to magnitude of treatment effect on infarct volume. NMD: normalized mean
difference. CI: confidence interval. (b) Contour-enhanced funnel plot showing standard error versus magnitude of treatment effect
estimate. See supplementary material section, Table 1 for details of individual doses and times of administration in each study
subdivision (a-i).
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signiﬁcant results is more likely to be submitted and
published than work with non-signiﬁcant results. We
did not observe any evidence of publication bias in
the funnel plot and the Egger test for signiﬁcance.
Relevance to clinical trials
Many interventions in the past that have shown eﬃcacy
in preclinical studies have then failed to exhibit eﬃcacy
in humans, possibly due to side eﬀects, narrow thera-
peutic time windows, and targeting of single pathological
pathways.3,4 Carnosine has a relatively long therapeutic
time window in animals studies. It also favorably inﬂu-
ences multiple pathways that are either activated or
involved in the extent of tissue injury during ischemia
such as excitoxicity, matrix metalloproteinase activity,
endogenous anti-oxidant levels, free radical generation,
pH buﬀering, and mitochondrial dysfunction.2,7,8–11
Taken together with the lack of reported side eﬀects in
human clinical studies in diabetes and heart failure,
makes carnosine a very promising neuroprotective
agent for acute stroke therapy.20,21.
Limitations
One limitation to this systematic review is the small
number of studies that met our inclusion criteria. The
limited data available meant there were insuﬃcient
comparisons to carry out stratiﬁed meta-analysis for
neurobehavioral score. Further, many of the studies
were carried out by groups led by the same senior inves-
tigator and this may limit the generalizability of these
Figure 3. (a) Effect of carnosine dose on infarct volume. (b) Effect of study characteristic variables on the estimate of efficacy (for
comparisons with carnosine dose 1000mg/kg). The vertical grey bar represents the 95% confidence limits of the overall estimate.
The horizontal error bars represent the 95% confidence intervals for the individual subgroup estimates. NMD: normalized mean
difference. CI: confidence interval.
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results. Moreover, all the studies were carried out in
healthy male animals without co-morbidity. To satisfy
Stroke Academic Industry Roundtable (STAIR), future
studies will need to test for eﬃcacy and safety in aged
animals, female animals and animals with co-morbidity
such as hypertension. In addition, future studies will need
to test eﬃcacy and safety of co-administrationwith tPA.22
Despite searching for relevant studies in major elec-
tronic databases, we cannot rule out the possibility of
missing studies.
Among the studies which used a dose of less than
1000mg/kg, all but one of the comparisons admini-
strated the drug 30min before the induction of ische-
mia, which limits interpreting the eﬀect of both time
of administration and dose. Similar problems might
have aﬀected other study characteristics. For exam-
ple, most of the low-dose studies used permanent
ischemia, and a greater proportion of them used
mice.
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